CDK-002 (exoSTING)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for CDK-002 (exoSTING), covering 2023-02-08 to 2023-02-08. Get the full timeline:
Most recent: Clinical Trial Update: A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors [Phase 1, Phase 2]